Amustaline (S-303) treatment inactivates high levels of Zika virus in red blood cell components

Transfusion

Volumn 57, Issue 3, 2017, Pages 779-789

  Laughhunn, Andrew ^a   Santa Maria, Felicia ^a   Broult, Julien ^b   Lanteri, Marion C ^a   Stassinopoulos, Adonis ^a   Musso, Didier ^c   Aubry, Maite ^c  

^a CERUS CORPORATION   (United States)

^b Centre de Transfusion Sanguine de la Polynésie Française   (France)

^c Institut Louis Malardé Pape'Ete   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMUSTALINE; GLUTATHIONE; VIRUS RNA; (N,N-BIS(2-CHLOROETHYL))-2-AMINOETHYL-3-((ACRIDIN-9-YL)AMINO)PROPIONATE; ACRIDINE DERIVATIVE; CHLORMETHINE DERIVATIVE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ERYTHROCYTE; HUMAN; LIMIT OF DETECTION; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS CULTURE; VIRUS INACTIVATION; VIRUS INFECTIVITY; VIRUS LOAD; ZIKA FEVER; ZIKA VIRUS; BLOOD; CHEMISTRY; DISINFECTION; FEMALE; MALE; PROCEDURES; VIROLOGY;

ACRIDINES; DISINFECTION; ERYTHROCYTES; FEMALE; HUMANS; MALE; NITROGEN MUSTARD COMPOUNDS; RNA, VIRAL; VIRUS INACTIVATION; ZIKA VIRUS;

EID: 85013116213     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13993     Document Type: Article

References (65)

1. Musso D, Gubler DJ. Zika virus. Clin Microbiol Rev 2016;29:487-524.
2. Gubler DJ, Kuno G, Markoff L. Fields' virology 2007; 5th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins;34:Flaviviruses:1153.
3. Duffy MR, Chen TH, Hancock WT, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med 2009;360:2536-43.
4. Cao-Lormeau VM, Roche C, Teissier A, et al. Zika virus, French Polynesia, South Pacific, 2013. Emerg Infect Dis 2014;20:1085-6.
5. Cao-Lormeau VM, Blake A, Mons S, et al. Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 2016;387:1531-9.
6. Musso D, Nhan T, Robin E, Roche C, Bierlaire D, Zisou K, Shan Yan A, Cao-Lormeau VM, Broult J. Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia, November 2013 to February 2014. Euro Surveill 2014;19:65.
7. Besnard M, Lastere S, Teissier A, Cao-Lormeau V, Musso D. Evidence of perinatal transmission of Zika virus, French Polynesia, December 2013 and February 2014. Euro Surveill 2014;19:61.
8. Musso D, Roche C, Robin E, et al. Potential sexual transmission of Zika virus. Emerg Infect Dis 2015;21:359-61.
9. Musso D, Nilles EJ, Cao-Lormeau VM. Rapid spread of emerging Zika virus in the Pacific area. Clin Microbiol Infect 2014;20:O595-6.
10. Campos GS, Bandeira AC, Sardi SI. Zika virus outbreak, Bahia, Brazil. Emerg Infect Dis 2015;21:1885-6.
11. Mlakar J, Korva M, Tul N, et al. Zika virus associated with microcephaly. N Engl J Med 2016;374:951-8.
12. Petersen LR, Jamieson DJ, Honein MA. Zika virus. N Engl J Med 2016;375:294-5.
13. Gulland A. Zika virus is a global public health emergency, declares WHO. BMJ 2016;352:i657.
14. Lysaght T, Lee TL, Watson S, et al. Zika in Singapore: insights from One Health and social medicine. Singapore Med J 2016;57:528-9.
15. McCarthy M. Four in Florida are infected with Zika from local mosquitoes. BMJ 2016;354:i4235.
16. World Health Organisation. Zika virus, microcephaly and Guillain-Barre syndrome situation report. [Cited 2016 Nov. 4]. http://apps.who.int/iris/bitstream/10665/254507/1/zikasitrep2Feb17-eng.pdf?ua=1:1-6.
17. Messina JP, Kraemer MU, Brady OJ, et al. Mapping global environmental suitability for Zika virus. Elife 2016;5.
18. Stramer SL, Fang CT, Foster GA, et al. West Nile virus among blood donors in the United States, 2003 and 2004. N Engl J Med 2005;353:451-9.
19. Tomashek KM, Margolis HS. Dengue: a potential transfusion-transmitted disease. Transfusion 2011;51:1654-60.
20. Hoad VC, Speers DJ, Keller AJ, et al. First reported case of transfusion-transmitted Ross River virus infection. Med J Aust 2015;202:267-70.
21. Centers for Disease Control and Prevention. Transfusion-related transmission of yellow fever vaccine virus—California, 2009. MMWR Morb Mortal Wkly Rep 2010;59:34-7.
22. Musso D, Broult J, Bierlaire D, Lanteri MC, Aubry M. Prevention of transfusion-transmitted Zika virus in French Polynesia, nucleic acid testing versus pathogen inactivation. ISBT Science Series 2016;10.1111/voxs.12335.
23. Bierlaire D, Beau F, Lastere S, et al. Virus ZIKV en Polynesie Francaise: hemovigilance receveur. Transfus Clin Biol 2014;21:234.
24. ProMED-mail. Zika virus - Americas, Atlantic Ocean. http://www.promedmail.org/, 2015.
25. Barjas-Castro ML, Angerami RN, Cunha MS, et al. Probable transfusion-transmitted Zika virus in Brazil. Transfusion 2016;56:1684-8.
26. Motta IJ, Spencer BR, Cordeiro da Silva SG, et al. Evidence for transmission of Zika virus by platelet transfusion. N Engl J Med 2016;375:1101-3.
27. Lanteri MC, Kleinman SH, Glynn SA, et al. Zika virus: a new threat to the safety of the blood supply with worldwide impact and implications. Transfusion 2016;56:1907-14.
28. Musso D, Stramer SL, AABB Transfusion-Transmitted Diseases Committee, et al. Zika virus: a new challenge for blood transfusion. Lancet 2016;387:1993-4.
29. Musso D, Gould E, Lanteri M. Documentation of transfusion-transmitted arbovirus infections in endemic areas. Transfusion 2016;56:3143-4.
30. Control ECfDPa. Zika virus infection outbreak, French Polynesia. http://ecdc.europa.eu/en/publications/publications/zika-virus-french-polynesia-rapid-risk-assessment.pdf, 2014.
31. U.S Department of Health and Human Services. February: Recommendations for Donor Screening, Deferral, and Product Management to Reduce the Risk of Transfusion Transmission of Zika Virus - Guidance for Industry. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/UCM486360.pdf, Food and Drug Administration 2016; Center for Biologics Evaluation and Research.
32. U.S. Department of Health and Human Services. August: Revised Recommendations for Reducing the Risk of Zika Virus Transmission by Blood and Blood Components Guidance for Industry. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/UCM518213.pdf, Food and Drug Administration 2016; Center for Biologics Evaluation and Research.
33. World Health Organization. Maintaining a safe and adequate blood supply during Zika virus outbreaks. http://apps.who.int/iris/bitstream/10665/204436/1/WHO_ZIKV_HS_16.1_eng.pdf?ua=1 WHO/ZIKV/HS/16.1, February 2016.
34. American Association of Blood Banks. Updated Recommendations for Zika, Dengue, and Chikungunya Viruses. www.aabb.org/programs/publications/bulletins/Documents/ab16-07.pdf AABB Association Bulletin #16-07, 2016.
35. Allain JP, Bianco C, Blajchman MA, et al. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Med Rev 2005;19:110-26.
36. Mufti NA, Erickson AC, North AK, et al. Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC. Biologicals 2010;38:14-9.
37. Wiltshire M, Meli A, Schott MA, et al. Quality of red cells after combination of prion reduction and treatment with the intercept system for pathogen inactivation. Transfus Med 2016;26:208-14.
38. Epstein JS, Vostal JG. FDA approach to evaluation of pathogen reduction technology. Transfusion 2003;43:1347-50.
39. Musso D, Richard V, Broult J, et al. Inactivation of dengue virus in plasma with amotosalen and ultraviolet A illumination. Transfusion 2014;54:2924-30.
40. Richard V, Viallon J, Cao-Lormeau VM. Use of centrifugal filter devices to concentrate dengue virus in mosquito per os infection experiments. PLoS One 2015;10:e0138161.
41. Aubry M, Richard V, Green J, et al. Inactivation of Zika virus in plasma with amotosalen and ultraviolet A illumination. Transfusion 2016;56:33-40.
42. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Hyg 1938;27:493-7.
43. Gubler DJ. Resurgent vector-borne diseases as a global health problem. Emerg Infect Dis 1988;4:442-50.
44. Weaver SC, Reisen WK. Present and future arboviral threats. Antiviral Res 2010;85:328-45.
45. Prevention CfDCa. Guidance for U.S. Laboratories testing for Zika virus infection. www.cdc.gov/zika/pdfs/laboratory-guidance-zika.pdf. In: Prevention CfDCa, ed. Centers for Disease Control and Prevention, Morbidity and Mortality Weekly report June, 2016.
46. Musso D, Baud D, Fredman D. Should testing of donors of substances of human origin be retected to area with active Zika virus circulation? Lancet Infect Dis 2016;16:1108-9.
47. Nkohkwo A, Agbor G, Asongalem E, et al. Whole blood pathogen reduction technology and blood safety in sub-Saharan Africa: a systemic review with regional discussion. Afr J Lab Med 2016;5, doi:10.4102/ajlm.v5i1.363.
48. Rasongles P, Angelini-Tibert MF, Simon P, et al. Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Reunion. Transfusion 2009;49:1083-91.
49. Tsetsarkin KA, Sampson-Johannes A, Sawyer L, et al. Photochemical inactivation of chikungunya virus in human apheresis platelet components by amotosalen and UVA light. Am J Trop Med Hyg 2013;88:1163-9.
50. Dupuis K, Arnold D, Sawyer L. High titers of dengue virus in platelet concentrates are inactivated by treatment with amotosalen and UVA light [abstract]. Transfusion 2012;52:225A.
51. Lin L, Hanson CV, Alter HJ, et al. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005;45:580-90.
52. Brixner V. Clinical Safety and efficacy of red blood cell components treated with the S-303 pathogen inactivation system - a randomized controlled double-blind phase 3 study in patients requiring transfusion support of acute anemia. 25th Regional Congress of the International Society of Blood Transfusion. London, United Kingdom: Vox Sanguinis, 2015:28–9.
53. Kleinman S, Stassinopoulos A. Risks associated with red blood cell transfusions: potential benefits from application of pathogen inactivation. Transfusion 2015;55:2983-3000.
54. Henschler R, Seifried E, Mufti N. Development of the S-303 pathogen inactivation technology for red blood cell concentrates. Transfus Med Hemother 2011;38:33-42.
55. North A, Ciaravino V, Mufti N, et al. Preclinical pharmacokinetic and toxicology assessment of red blood cells prepared with S-303 pathogen inactivation treatment. Transfusion 2011;51:2208-18.
56. Stassinopoulos A, Schott MA, Castro GM, et al. Elimination of immunoreactivity of red blood cells treated with a modified S-303 pathogen inactivation process. 2004. ASH annual meeting, San Diego, CA, USA. Blood 2004;104;2703.
57. Bakkour S, Chafets DM, Wen L, et al. Assessment of nucleic acid modification induced by amotosalen and ultraviolet A light treatment of platelets and plasma using real-time polymerase chain reaction amplification of variable length fragments of mitochondrial DNA. Transfusion 2016;56:410-20.
58. Sawyer L, Hanson D, Castro G, et al. Inactivation of parvovirus B19 in human platelet concentrates by treatment with amotosalen and ultraviolet A illumination. Transfusion 2007;47:1062-70.
59. Aubry M, Richard V, Green J, Broult J, Musso D. Amotosalen and ultraviolet A illumination inactivation of Zika virus in plasma. International Society of Blood Transfusion London UK: Vox Sanguinis 2015:189–90.
60. Busch MP. Zika and the safety of the US blood supply. Adv Hematol 2016;14:677-9.
61. Jimenez A, Shaz BH, Bloch EM. Zika Virus and the Blood Supply: What Do We Know? Transfus Med Rev 2017;31:1–10. doi: 10.1016/j.tmrv.2016.08.001. Epub 2016 Aug 9.
62. Lustig Y, Mendelson E, Paran N, et al. Detection of Zika virus RNA in whole blood of imported Zika virus disease cases up to 2 months after symptom onset, Israel, December 2015 to April 2016. Euro Surveill 2016;21.
63. Lanteri MC, Lee TH, Wen L, et al. West Nile virus nucleic acid persistence in whole blood months after clearance in plasma: implication for transfusion and transplantation safety. Transfusion 2014;54:3232-41.
64. Kuehnert MJ, Epstein JS. Assuring blood safety and availability: Zika virus, the latest emerging infectious disease battlefront. Transfusion 2016;56:1669-72.
65. Santa Maria F, Laughhunn A, Lenhoff R, Stassinopoulos A. Effective Inactivation of Zika Virus by Nucleic Acid Targeted Adducts 2016 AABB annual meeting. Orlando, FL, USA. Transfusion 2016;56 Supplement S4:11A.